In this article, we will discuss Ramucirumab (15). So, let;s get started. Infusion-Related Reactions (IRRs) Prior to the institution of premedication recommendations across clinical trials of Ramucirumab, infusion-related reactions (IRRs) occurred in 6 out of 37 patients (16%), including two severe events. The majority of IRRs across trials occurred during or following a first or […]
Category: Ramucirumab
In this article, we will discuss Ramucirumab (14). So, let’s get started. Warnings (3) Hypertension An increased incidence of severe hypertension occurred in patients receiving Ramucirumab as a single agent (8%) as compared to placebo (3%) and in patients receiving Ramucirumab plus paclitaxel (15%) as compared to placebo plus paclitaxel (3%). Control hypertension prior to […]
In this article, we will discuss Ramucirumab (13). So, let’s get started. Warnings-2 Arterial Thromboembolic Events Serious, sometimes fatal, arterial thromboembolic events (ATEs) including myocardial infarction, cardiac arrest, cerebrovascular accident, and cerebral ischemia occurred in clinical trials including 1.7% of 236 patients who received Ramucirumab as a single agent for gastric cancer in clinical studies. […]
In this article, we will discuss Ramucirumab (12). So, let’s get started. Warnings (1) Hemorrhage Ramucirumab increased the risk of hemorrhage and gastrointestinal hemorrhage, including severe and sometimes fatal hemorrhagic events. In Study 1, the incidence of severe bleeding was 3.4% for Ramucirumab and 2.6% for placebo. In Study 2, the incidence of severe bleeding […]
In this article we will discuss Ramucirumab (11)
In this article we will discuss Ramucirumab (10)